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 2 
Abstract (75 word limit) 25 
Diabetic foot ulcer treatment currently focuses on targeting bacterial biofilms, 26 
while dismissing fungi. To investigate this we used an in vitro biofilm model 27 
containing bacteria and fungi, reflective of the wound environment, to test the 28 
impact of antimicrobials. Here we showed that while mono-treatment 29 
approaches influenced biofilm composition it had no discernible effect on 30 
overall quantity. Only by combining bacterial and fungal specific antibiotics 31 
were we able to decrease the biofilm bioburden, irrespective of composition.   32 
 3 
Diabetic foot ulcers (DFU) are an increasing healthcare burden, and cause 33 
excessive amounts of patient morbidity and mortality. It is known that infection 34 
both impairs healing and is linked to the recurrence of ulcers (1). It has been 35 
shown that chronic wounds often harbour pathogenic biofilms of polymicrobial 36 
nature, and are commonly recalcitrant to treatment (2-5). Guidelines suggest 37 
the initial use of oral antibiotics for empirical therapy with activity against Gram 38 
positive organisms, especially penicillins such as flucloxacillin (6, 7). Further 39 
coverage is provided by other antibiotics, such as the fluoroquinolone 40 
ciprofloxacin (7). Despite these chemotherapeutic approaches, resolution of 41 
infection is often hindered because of the failure to account for co-infecting 42 
pathogenic fungi (8). Indeed, fungal infection in DFU is under recognised, 43 
though recently some studies are beginning to shed light on the significant 44 
involvement of the wound mycobiome (9). While antifungal treatment have 45 
been shown to improve DFU outcome, they are only used routinely to treat 46 
superficial fungal infections in diabetics, such as onychomycosis (10, 11). 47 
Therefore, it is not a great leap to suspect fungal components as a key 48 
contributor to pathogenic DFU biofilms.  49 
 50 
Characterised laboratory strains were used to create biofilms in standard 96-51 
well plates, including the bacteria Pseudomonas aeruginosa PA14 and 52 
Staphylococcus aureus ATCC 13420, and the yeast Candida albicans SC5314 53 
(12). Biofilm antimicrobial susceptibility testing was carried out as described 54 
previously by our group to determine the sessile minimum inhibitory 55 
concentrations (MICs) (13). Briefly, mono-species and co-culture biofilms were 56 
grown in Mueller Hinton (bacterial cultures) or RPMI broth (fungal cultures) 57 
before being treated with the flucloxacillin, ciprofloxacin, or fluconazole (Sigma, 58 
Dorset, UK) which are common clinically at a range of concentrations (0.125 to 59 
128 mg/L) (6, 7, 11). Viability post-treatment was assessed using alamar 60 
Blue™ metabolic dye. Here it was shown that an increase in species diversity 61 
leads to elevated viability following treatment (Figure 1, p<0.01), as evidenced 62 
by S. aureus co-culture and triadic biofilms after ciprofloxacin therapy. A similar, 63 
but less dramatic, effect was observed with flucloxacillin, though for 64 
fluconazole no discernible effect was observed (Figure S1). This indicates that 65 
increased complexity of a biofilm community and physical structure provided by 66 
 4 
C. albicans leads to enhanced resistance as has been shown elsewhere (14, 67 
15).  68 
 69 
Our group has recently created and described an in vitro interkingdom biofilm 70 
model that reflects a chronic wound environment, a model formed within a 71 
three-dimensional cellulose matrix (12). We therefore aimed to use this model 72 
to characterise in vitro responses to antibiotic pressure in a triadic interkingdom 73 
biofilm model that is reflective of the chronic wound environment. Triadic 74 
biofilms in the cellulose model were created by standardising all three 75 
microorganisms to 1 x 106 CFU/mL in PBS, and incubating with 1.25 cm² 76 
sections of cellulose matrix for 2 h at 37°C with agitation. The matrix was then 77 
placed on top of a 50% serum hydrogel surface and incubated at 37°C for 24 h 78 
(12). Following biofilm development, these were treated with 128 mg/mL 79 
flucloxacillin, ciprofloxacin and fluconazole, either alone or in combination, for a 80 
further 24 h at 37°C alongside untreated controls. All testing was carried out in 81 
triplicate, on three separate occasions. To differentiate between live and dead 82 
cells, a qPCR based assay (16-19) was used to assess the viable composition 83 
of the biofilms with species specific primers (12, 19). This assay utilises 84 
propidium monoazide, a DNA intercalating dye, which binds to DNA in cells 85 
with a compromised membrane preventing this DNA from being amplified in 86 
downstream PCR. Therefore only DNA from viable cells with intact membranes 87 
is detected. MasterPure™ Yeast DNA extraction kits were used as per 88 
manufacturer’s instructions (Epicentre, Cambio, Cambridge, UK) to process all 89 
samples. For qPCR a Fast SYBR® Green Master Mix (Life Technologies, 90 
Paisley, UK) was used with primer sequences and thermal profile previously 91 
defined (12). Each sample was analysed in duplicate using Step One Real-92 
Time PCR system and software (Life Technologies, Paisley, UK). Samples 93 
were quantified to calculate the colony forming equivalent (CFE) based upon a 94 
standard curve per reaction performed. Results were also confirmed by colony 95 
forming unit (CFU) counts using the Miles and Misra technique (20). 96 
The cellulose matrix model has already been shown to create more resilient 97 
biofilms (12), and when treated with elevated levels of antibiotics (128 mg/L) 98 
there was little impact on the viable cells within the matrix, though 99 
 5 
compositionally the biofilms were affected (Figure 2A). This implies that 100 
eliminating one microbial component of the biofilm through targeted therapy 101 
creates a niche for the other species to thrive. For example, fluconazole 102 
treatment significantly decreased C. albicans by approximately 1 x log10 103 
(p<0.05). In contrast, a combined treatment of flucloxacillin/ciprofloxacin 104 
resulted in a three-fold increase in C. albicans (Figure 2B). In addition to 105 
consideration of the biofilm composition, the biovolume is equally important 106 
given that a C. albicans cell is approximately ten times the size of a S. aureus 107 
cell. Consequently, even in biofilms where C. albicans in low abundance, the 108 
yeast and hyphal cells still provide physical structure and support to biofilm 109 
through its spatial dominance. The only treatment observed to cause a 110 
substantial decrease in all three microbial components, and an overall 111 
reduction in viable cell composition, was the combination all three 112 
antimicrobials (Figure 3). Hierarchical clustering analysis also shows that the 113 
C. albicans population is very closely linked to the total CFE present, 114 
suggesting it is a key driving force within the biofilm community (Figure 3). 115 
The data from this investigation suggests that antifungal drugs should be 116 
included in empirical therapy options alongside antibiotics. It has been recently 117 
shown that the hyphal structure and extracellular matrix of C. albicans 118 
mycofilms support bacterial growth, leading to a more resilient biofilms in terms 119 
of antibiotics and antifungals (14, 15). These key findings indicate that 120 
disrupting and/or impeding this supportive mycofilm structure could lead to a 121 
physical collapse of the polymicrobial community. Fungi are increasingly 122 
recognised as a key contributor to biofilms in DFU, and we have shown here 123 
that C. albicans appears to be an important element behind the recalcitrant 124 
nature of these biofilms. Therefore, it is imperative to consider a treatment 125 
covering these major pathogens, rather than consider them as having a 126 
supporting role. Inclusion of antifungals into routine treatment strategies could 127 
allow for easier disruption of the biofilm, decreasing microbial load in DFU, and 128 
ultimately improving patient outcomes. 129 
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Figure 1: Increased microbial complexity of biofilms leads to reduced 1 
susceptibility to antimicrobial agents. Biofilm (sessile) MIC values were 2 
calculated using the alamar blue® viability test. All tests were carried out in 3 
quadruplicates on three separate occasions as described in the methods. 4 
Monoculture (Sa) biofilms were compared to co-culture biofilms (Sa + Ca, Sa + 5 
Pa) and triadic biofilms (Sa + Ca + Pa). Data was analysed using a two-way 6 
ANOVA with Tukey’s multiple comparison test to compare each mono- or co-7 
culture at each antimicrobial concentration. 8 
 9 
Figure 2: Triadic biofilm composition is influenced by antimicrobial 10 
treatment. Antibiotics, flucloxacillin (FLX) and ciprofloxacin (CIPX), and 11 
antifungal, fluconazole (FLC), were used to treat the biofilms, either alone or in 12 
combination as described in the methods. Biofilm percentage composition is 13 
shown in the bar graphs (A), while absolute numbers of viable colony forming 14 
equivalents (CFEs) present is shown below (B). Treated biofilms were 15 
compared to untreated controls using a two tailed unpaired t-test (* p<0.05). 16 
 17 
Figure 3: Triple antimicrobial treatment elicits the largest impact on 18 
biofilms. The heat map shows a fold-change increase in viable CFE (red), 19 
decrease (blue), or no change (white) after treatment with flucloxacillin (FLX), 20 
ciprofloxacin (CIPX), and fluconazole (FLC), either alone or in combination. 21 
Hierarchical clustering analysis (left) shows that the total bioburden is closely 22 
related to C. albicans, suggesting this is the component of the biofilm that is 23 
integral to infection. 24 
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